N. Lai

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Yu Wang, T. Schall, J. Jaén, 2010, Journal of Pharmacology and Experimental Therapeutics.

Evidence for NK Cell Subsets Based on Chemokine Receptor Expression1

L. Lanier, T. Schall, R. Berahovich, 2006, The Journal of Immunology.